3 Biotechs That More Than Doubled Investors' Cash In 2017

Published: Jun 19, 2017

We are almost half way through 2017 and the biotech sector, which had a rough and challenging 2016, has been showing signs of recovery despite some ups and downs. Year-to-date (YTD), the NASDAQ Biotechnology Index is up 10.4% providing a glimmer of hope to biotech investors who saw the Index sliding 19.1% in 2016.

While the drug pricing issue remains a headline risk this year as well, confidence in the sector has been boosted by strong results, R&D success and innovation, FDA approvals, ramp up in new product sales and continued strong performance from legacy products. There is also a lot of hope that M&As will pick up this year.

Back to news